Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4831 in heart failure with left ventricular ejection fraction greater than 40%
NL-OMON51637Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF) (5 arms), sponsored by AstraZeneca. Primary endpoints: Change from baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score at 16 weeks versus placebo, Change from baseline in 6-minute walk distance at 16 weeks versus placebo and 2 more. Started Oct 2022; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON51637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51637.